LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that the Securities and Exchange Commission (SEC) has declared effective the registration statement on Form S-1 filed by CytRx’s majority-owned subsidiary RXi Pharmaceuticals Corporation (RXi).
